Literature DB >> 33965509

Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1.

Yabing Du1, Xiaoyi Shi2, Wang Ma3, Peihao Wen4, Pu Yu5, Xin Wang6, Pengli Fang7, Aixia Chen8, Zhiqiang Gao9, Kang Cui10.   

Abstract

Phthalates (PAEs) are considered endocrine-disrupting chemicals (EDCs), a series of compounds able to disrupt the normal regulation of the human endocrine-system. In the present study, we investigated the roles of four PAEs, butyl benzyl phthalate (BBP), dibutyl phthalate (DBP), dimethyl phthalate (DMP), and diethyl phthalate (DEP), in hepatocellular carcinoma (HCC) cells. We define novel roles for the PAEs on the migration of HCC cells via their enhancing of the interaction between the pregnane X receptor (PXR) and E26 transformation specific sequence 1 (ETS-1). Our results indicate that PAEs induced the transcriptional activation of ETS-1 and PXR. PXR activated by PAEs could bind to ETS-1 directly and enhanced the activity of ETS-1, which resulted in the induction of invasion-related ETS-1 target genes. The "LXXLL" motif in the ETS-1C-terminal was essential for the interaction between PXR and ETS-1 induced by PAEs. Treatment of PAEs promoted the nuclear accumulation of ETS-1 or the recruitment of ETS-1, but not in cells expressing ETS-1 with a mutated LXXLL motif in its downstream gene promoter region, or following transfection of PXR siRNA. Treatment with the PXR antagonist ketoconazole almost completely inhibited the effects of PAEs. Moreover, PAEs enhanced the in vitro or in vivo invasion of HCC cells via PXR/ETS-1. Therefore, our results not only contribute to a better understanding of HCC, but also extended the roles of EDCs regulating human malignancies.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  E26 transformation specific sequence 1; Endocrine-disrupting chemicals; Hepatocellular carcinoma; Phthalates; Pregnane X receptor

Mesh:

Substances:

Year:  2021        PMID: 33965509     DOI: 10.1016/j.phrs.2021.105648

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  12 in total

1.  A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma.

Authors:  Da Mao; Meihong Xu; Qiyu Jiang; Huiwei Sun; Fang Sun; Ruichuang Yang; Yantao Chai; Xiaojuan Li; Boan Li; Yong Li
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

2.  Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs.

Authors:  Fengxia Du; Huiwei Sun; Fang Sun; Shiwei Yang; Haidong Tan; Xiaojuan Li; Yantao Chai; Qiyu Jiang; Dongdong Han
Journal:  Front Pharmacol       Date:  2022-06-07       Impact factor: 5.988

3.  A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs.

Authors:  De-Bin Ma; Xing-Yu Liu; Hui Jia; Yingshi Zhang; Qiyu Jiang; Huiwei Sun; Xiaojuan Li; Fang Sun; Yantao Chai; Fan Feng; Lei Liu
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

4.  Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation.

Authors:  Xiao-Zheng Zou; Jun-Feng Hao; Xiu-Hua Zhou
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

5.  Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma.

Authors:  Mei Luo; Huiwei Sun; Qiyu Jiang; Yantao Chai; Congshu Li; Bin Yang; Zhixian Hong
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

6.  A Novel Small Molecular Inhibitor of DNMT1 Enhances the Antitumor Effect of Radiofrequency Ablation in Lung Squamous Cell Carcinoma Cells.

Authors:  Yuan-Yuan Liu; Cheng-Zhi Ding; Jia-Ling Chen; Zheng-Shuai Wang; Bin Yang; Xiao-Ming Wu
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

7.  Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma.

Authors:  Hao Yang; Guanglin Lei; Fang Sun; Jinxia Cheng; Jin Yan; Shaogeng Zhang; Penghui Yang
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

8.  The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients.

Authors:  Da-Li Zhang; Dan-Ni Feng; Xi He; Xiao-Feng Zhang; Li-Xin Li; Zhi-Jie Li; Xiao-Feng Niu; Yun-Long Zhuang; Zhen-Wen Liu; Xu-Dong Gao; Hong-Bo Wang
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

9.  MTBP enhances the activation of transcription factor ETS-1 and promotes the proliferation of hepatocellular carcinoma cells.

Authors:  Hongbo Wang; Fang Chu; Li Zhijie; Qian Bi; Li Lixin; Yunlong Zhuang; Zhang Xiaofeng; Xiaofeng Niu; Dali Zhang; He Xi; Bo-An Li
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

10.  MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor.

Authors:  Qiyu Jiang; Yan Ma; Jingjing Han; Jingdong Chu; Xuemei Ma; Lijun Shen; Bo Liu; Bo-An Li; Jun Hou; Qian Bi
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.